TScan Therapeutics reported cash from operations of -$27.54M and free cash flow of -$28.03M for the quarter ended Jun 2026, up 17.2% year over year. This cash flow statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||
| Net Income | -15.84M | -14.20M | -16.16M | -15.10M | -16.25M | -18.72M | -22.56M | -24.05M | -23.00M | -19.61M | -30.14M | -31.66M | -29.89M | -34.72M | -34.13M | -36.95M | -35.71M | -22.98M | -28.67M | -30.36M | |||||
| Share-based Compensation | 10.60M | 0.78M | 0.98M | 1.02M | 1.25M | 50.29M | 1.15M | 1.22M | 1.34M | 2.51M | 1.98M | 2.33M | 2.52M | 2.71M | 3.41M | 3.27M | 3.01M | 2.01M | 20.39M | 20.35M | |||||
| Gains from Investment Securities | -0.84M | -0.45M | -0.39M | -1.50M | -1.55M | -1.28M | -0.79M | -0.29M | -0.06M | ||||||||||||||||
| Cash from Operations | -13.64M | -14.38M | -20.12M | -13.37M | -17.00M | -16.01M | -23.59M | -22.02M | 8.02M | -23.77M | -29.27M | -26.23M | -27.92M | -27.41M | -37.59M | -33.27M | -32.46M | -32.00M | -24.28M | -27.54M | |||||
| Change in Working Capital | |||||||||||||||||||||||||
| Change in Account Payables | 0.88M | -2.46M | 0.82M | 0.41M | -1.12M | 0.41M | 0.49M | 0.37M | -0.27M | -0.64M | -0.41M | 0.40M | 1.02M | 0.98M | 0.56M | -0.43M | 1.93M | -5.07M | 1.04M | 0.84M | |||||
| Change in Accured Expenses | 1.71M | 1.85M | -2.80M | 0.61M | 1.60M | 1.32M | 0.74M | 0.78M | 1.02M | 1.31M | -1.60M | 1.95M | 0.53M | 3.66M | -5.41M | 2.67M | -1.11M | -3.38M | 0.90M | -0.74M | |||||
| Other Working Capital Changes | 0.82M | -0.44M | 0.66M | -1.15M | 0.73M | -2.28M | 1.18M | -2.91M | 0.69M | 0.05M | -0.26M | 0.86M | 0.39M | 0.89M | 1.17M | 1.19M | 0.46M | 0.09M | -0.13M | -0.48M | |||||
| Investing Activities | |||||||||||||||||||||||||
| Capital Expenditures | 0.85M | 2.21M | 0.53M | 1.89M | 0.42M | 1.38M | 0.84M | 0.42M | 1.42M | 0.47M | 0.70M | 0.86M | 1.37M | 0.89M | 1.53M | 1.28M | 1.43M | 0.17M | 0.07M | 0.49M | |||||
| Change in Acquisitions & Divestments | 45.65M | 15.50M | 56.00M | 75.51M | 76.00M | 76.25M | 34.00M | 15.00M | |||||||||||||||||
| Cash from Investing Activities | -0.85M | -2.21M | -0.53M | -1.89M | -0.42M | -1.38M | -0.84M | -0.42M | -61.41M | 1.91M | 36.16M | -33.72M | -82.35M | 27.29M | 13.53M | 48.44M | 32.58M | 14.83M | -0.07M | -0.47M | |||||
| Financing Activities | |||||||||||||||||||||||||
| Other financing activities | 89.48M | 0.09M | 0.03M | 0.01M | 0.07M | -0.08M | 0.26M | 128.01M | 30.00M | 0.12M | 0.07M | 0.06M | |||||||||||||
| Change in Capital Stock | |||||||||||||||||||||||||
| Net Shares Issued and Repurchased | 1.98M | 2.59M | 8.54M | 3.50M | 6.25M | ||||||||||||||||||||
| Net Equity Issued and Repurchased | 0.19M | -0.19M | |||||||||||||||||||||||
| Misc. | |||||||||||||||||||||||||
| Cash from Financing Activities | 90.61M | 0.12M | 0.09M | 0.03M | 29.13M | 0.11M | -0.25M | 0.02M | 0.26M | 161.59M | 1.23M | 45.69M | -0.53M | 0.12M | 0.07M | ||||||||||
| Change in Cash | 76.11M | -16.47M | -20.57M | -15.23M | 11.70M | -17.28M | -24.43M | 113.23M | -53.65M | -21.83M | 7.15M | 101.65M | -109.04M | 45.57M | -24.58M | 15.29M | 0.11M | -17.10M | -24.35M | -27.90M | |||||
| Free Cash Flow | -14.49M | -16.59M | -20.66M | -15.26M | -17.43M | -17.39M | -24.43M | -22.44M | 6.60M | -24.23M | -29.97M | -27.09M | -29.29M | -28.30M | -39.12M | -34.55M | -33.89M | -32.17M | -24.35M | -28.03M | |||||
| Net Cash Flow | 76.11M | -16.47M | -20.57M | -15.23M | 11.70M | -17.28M | -24.43M | -22.44M | -53.65M | -21.83M | 7.15M | 101.65M | -109.04M | 45.57M | -24.58M | 15.29M | 0.11M | -17.10M | -24.35M | -28.00M |